Clinical trial
A Combination Therapy In Patients With Social Anxiety Disorder
NCT00403962 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00403962 |
|---|---|
| Title | A Combination Therapy In Patients With Social Anxiety Disorder |
| Official title | A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Social Phobia |
| Intervention type | Drug |
| Interventions | vestipitant/paroxetine |
| Enrollment | 204 |
| Start date | Nov 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Nov 27, 2006 |
| Last update posted | Sep 15, 2016 |
| Countries | Denmark, Germany, Norway, South Africa |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: